Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus salivarius
- Development stage
- Phase 1
- Lead developer
- University College Cork
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Vaginal
01
Overview
Lactobacillus salivarius is a species of probiotic bacteria commonly found in the human gastrointestinal tract, oral cavity, and vagina. It is utilized in various probiotic formulations and has been investigated for its potential therapeutic effects across a range of conditions. Its mechanisms of action include modulating the microbiome, enhancing gut barrier function, inhibiting pathogenic bacteria, influencing immune responses, and producing beneficial metabolites. Clinical trials have explored its use in conditions such as mood disorders, neonatal hyperbilirubinemia, mastitis, infertility, oral health issues, inflammatory bowel diseases, gluten/wheat sensitivity, Group B Streptococcus colonization in pregnancy, Fragile X Syndrome, and pediatric asthma.
- Other names
- Ligilactobacillus salivarius
02
Targets
VEGFA (Vascular endothelial growth factor A)IL10 (Interleukin-10)TGFB (GARP–latent transforming growth factor beta 1 complex)GUSB (Beta-glucuronidase)
Beyond the preview
Go deeper on Lactobacillus salivarius.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus salivarius.